FIGURE 3.

Treatment regimen prescribing trends by stage or SCT subgroup, 2011–2019. Observed proportion of prescriptions for monotherapy, doublet, triplet, or quadruplet 1L therapy by (A) disease stage at diagnosis, (B) SCT eligibility at diagnosis, and (C) receipt of SCT therapy within 12 months of diagnosis. Early transplant recipients were defined as patients with a documented SCT within 12 months of the commencement of 1L therapy, measured from the start date of 1L treatment to the transplant date as noted in the medical record. Percentages for “other” treatment are all <1. 1L, front‐line; ISS, International Staging System; MM, multiple myeloma; SCT, stem cell transplant